Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Long-Term Investments (2020 - 2021)

Beam Therapeutics (BEAM) has disclosed Long-Term Investments for 2 consecutive years, with $24.5 million as the latest value for Q3 2021.

  • Quarterly Long-Term Investments changed N/A to $24.5 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $24.5 million through Sep 2021, changed N/A year-over-year, with the annual reading at $2.6 million for FY2020, N/A changed from the prior year.
  • Long-Term Investments for Q3 2021 was $24.5 million at Beam Therapeutics, down from $29.4 million in the prior quarter.
  • The five-year high for Long-Term Investments was $29.4 million in Q2 2021, with the low at $2.6 million in Q4 2020.